Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroOne Medical TechnologiesNMTC -1.27%34 Cyclically Adjusted PS Ratio is 3.39 as of Jul. 19, 2026, which is 88% below its 10-year median of 27.78. GuruFocus rates NMTC with a GF Score™ of 34/100 and a GF Value™ of $6.51 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 521 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks worse than 61.61% on this metric.
The historical rank and industry rank for NeuroOne Medical Technologies's Cyclically Adjusted PS Ratio or its related term are showing as below:
NMTC'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.39 Med: 27.78 Max: 821.25
Current: 3.39
During the past years, NeuroOne Medical Technologies's highest Cyclically Adjusted PS Ratio was 821.25. The lowest was 3.39. And the median was 27.78.
NMTC's Cyclically Adjusted PS Ratio is ranked worse than 61.61% of 521
companies
in the Medical Devices & Instruments industry
Industry Median: 2.28
vs NMTC: 3.39
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
NeuroOne Medical Technologies's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.219. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.69 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
NeuroOne Medical Technologies (NAS:NMTC) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
NeuroOne Medical Technologies Cyclically Adjusted PS Ratio Related Terms
NeuroOne Medical Technologies Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroOne Medical Technologies Cyclically Adjusted PS Ratio Chart
NMTC vs RDGL, TANAF, MODD: Cyclically Adjusted PS Ratio Comparison
For the Medical Devices subindustry, NeuroOne Medical Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroOne Medical Technologies Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's Cyclically Adjusted PS Ratio falls into.
NeuroOne Medical Technologies Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 3.39 mean?
NeuroOne Medical Technologies (NMTC) has a Cyclically Adjusted PS Ratio of 3.39 as of Jul. 19, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on NeuroOne Medical Technologies and its competitors. This is 88% below median its historical median of 27.78. Over the past decade, NeuroOne Medical Technologies' Cyclically Adjusted PS Ratio has ranged from 3.39 to 821.25. According to the industry distribution chart, NeuroOne Medical Technologies ranks #321 out of 521 companies in the Medical Devices & Instruments industry, placing it in the top 61.6%.
Is NeuroOne Medical Technologies' Cyclically Adjusted PS Ratio too high?
NeuroOne Medical Technologies' current Cyclically Adjusted PS Ratio of 3.39 is 88% below median its 10-year median of 27.78. Over the past 10 years, this metric has ranged from a low of 3.39 to a high of 821.25. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.28. NeuroOne Medical Technologies' value of 3.39 is 48.7% above this industry median. Based on the distribution chart, NeuroOne Medical Technologies ranks #321 out of 521 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NeuroOne Medical Technologies has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' Cyclically Adjusted PS Ratio compare to RDGL and TANAF?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #321 out of 521 companies for Cyclically Adjusted PS Ratio. This places NeuroOne Medical Technologies in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.28. NeuroOne Medical Technologies' value of 3.39 is 48.7% above this benchmark. Historically, NeuroOne Medical Technologies' own Cyclically Adjusted PS Ratio has ranged from 3.39 to 821.25 over the past decade. While the company's 10-year median is 27.78 vs. the industry median of 2.28, NeuroOne Medical Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.28, based on 521 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroOne Medical Technologies's current Cyclically Adjusted PS Ratio of 3.39 is 48.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on NeuroOne Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroOne Medical Technologies's current Cyclically Adjusted PS Ratio is 3.39, which is 88% below median its own 10-year median of 27.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
Based on GuruFocus' analysis, NeuroOne Medical Technologies (NMTC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.51, compared to a current price of $2.34 — trading 64.1% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 3.39, which is 88% below median its 10-year median of 27.78 and 48.7% above the Medical Devices & Instruments industry median of 2.28. NeuroOne Medical Technologies' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current Cyclically Adjusted PS Ratio is 3.39 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroOne Medical Technologies (NMTC) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroOne Medical Technologies stock appears to be undervalued.
The current stock price of $2.34 is trading 64.1% below its estimated GF Value™ of $6.51.
GuruFocus considers NeuroOne Medical Technologies to be Possible Value Trap.
Key valuation signals for NMTC:
Cyclically Adjusted PS Ratio: 3.39 (88% below median its 10-year median of 27.78)
GF Value™: $6.51 vs. price of $2.34 (64.1% below fair value)
Industry Position: 48.7% above the Medical Devices & Instruments median (#321 of 521)
No single metric tells the full story. See the NMTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroOne Medical Technologies Business Description
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
34GF Score
Get the complete analysis for NMTC
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMTC has been successfully added to your 
